Dr.WU Liang-cun applys constitution doctrine of TCM in treating geriatric oncology patients.According to the classification of constitutions and the features of geriatric oncology’s pathogenesis,Dr.WU Liang-cun advocates the principle of comprehensive treatment and stage treatment.There are different rating in different fuzhenquxie period basis on the patient’s condition of zhen-xie and xu-shi.Dr.WU Liang-cun always pays attention to applying wenshen pharmacy in his prescription.

Objective] To summarize national famous doctor of traditional Chinese medicine-Wu Liangcun ’s experience about the clinical treatment of ovarian cancer. [Method] By studying and following Professor Wu Liangcun to diagnose, this paper discusses Professor Wu ’s academic views and clinical experience of diagnosis and treatment of ovarian cancer respectively from the aspects such as etiology and pathogenesis, and treatment based on syndrome differentiation. It expounds the characteristics of his prescription and also gives proven cases. [Result]Professor Wu Liangcun proposes that the pathogenesis of ovarian cancer is mainly congenital deficiency and physical weakness resulted from cold coagulation, qi stagnation, blood stasis and phlegmatic hygrosis. All these remain a standstill, gather together and become a disease. He uses the syndrome differentiation method to divide the common ovarian cancer into four types:blood stasis and vital energy retardation, phlegm dampness condensation, deficiency of liver-yin and kidney-yin, asthenia of qi and blood. In the treatment, he organically combines the dialectics and the differentiation of disease; In the selection of drugs, he streamlines the prescription and the drug, which maximizes the efforts of the drugs and has good efforts in clinic.[Conclusion] Professor Wu Liangcun is good at making a diagnosis and giving treatment of ovarian cancer in combination with disease and syndrome, and he uses medicine flexibly. It has a very good effect and practical value for guiding clinic, and it should be promoted.

Objective To systematically evaluate the effectiveness of Chinese medicine(CM) combined with chemotherapy in preventing stageⅡ-Ⅲ colorectal cancer patients from postoperative recurrence and metastasis. Methods Databases of PubMed, EMBase, Cochrane Library, China National Knowledge Information(CNKI), VIP Database, Wanfang Database, and SinoMed were retrieved to collect randomized controlled trials(RCTs) of CM combined with chemotherapy in preventing stageⅡ-Ⅲ colorectal cancer patients from postoperative recurrence and metastasis. And then the quality of the included RCTs was evaluated systematically. Results Seven RCTs involving 700 cases of stageⅡ-Ⅲ colorectal cancer patients were included, 355 patients in treatment group were treated with CM combined with chemotherapy, and 345 patients in control group were treated with chemotherapy alone. The results of Meta-analysis showed that treatment group was superior to the control group in preventing the recurrence and metastasis of colorectal cancer one , 2 and 3 year(s) after the radical surgery, showing statistically significant differences(P < 0.05), while the difference of five-year recurrence and metastasis rate was not statistically significant between the two groups(P > 0.05). At the same time, CM combined with chemotherapy had better effect than chemotherapy alone on prolonging the time for recurrence and metastasis, improving performance status and relieving the symptoms, the difference being significant(P<0.05). Conclusion CM combined with chemotherapy exerts better effect than chemotherapy alone in preventing stageⅡ-Ⅲ colorectal cancer patients from postoperative recurrence and metastasis and onimproving the quality of life of the patients. However, for the low methodological quality of the included trials, the conclusion still needs more large-size sample, multiple-center, and high-quality clinical trials to be confirmed.

From the ethanol extract of Adina rubella;twelve compounds were isolated by silica gel and ODS col-umn chromatography.Their structures were identified by spectroscopic analysis as:5;7-dihydroxy-2-methyl-chromone-7-O-β-D-glucopyranoside(1);scopolin(2);(+)-lyoniresinol-3a-O-β-D-glucopyranoside(3);(6S;7R;8R)-7a-[(β-D-glucopyranosyl)oxy]lyoniresinol(4);harman-3-carboxylic acid(5);lyaloside(6);3-oxoquinovid acid(7);oleanolic acid(8);3-acetyl oleanolic acid(9);quinovic acid 3-O-β-D-glucopyranosyl-28-O-β-L-rham-nopyranosyl ester(10);quinovic acid 3-O-β-D-glucopyranosiyl-28-O-β-D-glucopyranosyl ester(11)and pyrocin-cholic acid 3-O-α-L-rhamnopyranosyl-28-[β-D-glucopyranosyl-(1 →6)-O-β-D-glucopyranosyl]ester(12). Compounds 3;4;6;8-10 were isolated from this plant for the first time.

Malignant cancer is a kind of fatal disease with severe threat to human health and social development, and seeking a scientific method for the proper diagnosis, treatment and assessment has become one of the most important public health problems in recent years. With the constant development in healthcare industry, traditional methods of tumor screening, prevention and prognosis assessment have made a rapid progress. However, owing to the characteristics of tumor heterogeneity and patient individuation, precision medicine mode in disease screening, diagnosis and treatment will become a general trend in future medical development. As an important part in precision medicine, gene variation detection in the field of tumors involves several aspects, including early screening, recurrence monitoring, guidance on use of targeted drugs and assessment of efficacy and prognosis etc; However, there are still many limitations in its clinical practice. Therefore, further research is needed to promote the development of tumor precision medicine. In this paper, the development history of gene variation detection and its application progress in precision medicine of malignant tumors are comprehensively discussed.